Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus vaccine live bivalent
- Development stage
- Approved
- Lead developer
- Institute of Experimental Medicine
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
A bivalent live attenuated influenza vaccine (LAIV) designed to protect against swine influenza A virus (swIAV). The vaccine specifically targets the H1N2 and H3N2 subtypes using elastase-dependent, non-virulent strains (A/Swine/Alberta/SD0191/2016 and A/Swine/Saskatchewan/SD0069/2015). By utilizing elastase-dependent attenuation, the vaccine is restricted to replication only in the presence of specific exogenous enzymes, enhancing safety. It works by inducing hemagglutination inhibition (HI) antibodies and IFN-γ secreting cells, effectively reducing viral replication and lung pathology in swine.
- Other names
- elastase-dependent bivalent live attenuated vaccineVIDO swine influenza vaccinebivalent LAIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza virus vaccine live bivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus vaccine live bivalent.